share_log

CVS Health | UPLOAD: Others

CVS Health | UPLOAD: Others

西維斯健康 | UPLOAD:其他
美股SEC公告 ·  11/19 13:35

Moomoo AI 已提取核心訊息

CVS Health reported strong Q3 2023 results, with total revenues up 10.6% YoY to $89.8B and adjusted EPS of $2.21, beating expectations. The company raised its full-year 2023 GAAP EPS guidance to $6.37-$6.61 and adjusted EPS guidance to $8.50-$8.70.Health Services segment revenues grew 8.4% YoY to $46.9B, driven by pharmacy claims growth and brand inflation. Health Care Benefits segment revenues increased 16.9% YoY to $26.3B, reflecting Medicare and Medicaid membership growth. Pharmacy & Consumer Wellness segment revenues rose 6.6% YoY to $28.9B.CVS Health reaffirmed its commitment to its strategy and long-term growth targets. The company expects to deliver low double-digit adjusted EPS growth in 2024 and beyond, driven by core business growth and strategic initiatives.
CVS Health reported strong Q3 2023 results, with total revenues up 10.6% YoY to $89.8B and adjusted EPS of $2.21, beating expectations. The company raised its full-year 2023 GAAP EPS guidance to $6.37-$6.61 and adjusted EPS guidance to $8.50-$8.70.Health Services segment revenues grew 8.4% YoY to $46.9B, driven by pharmacy claims growth and brand inflation. Health Care Benefits segment revenues increased 16.9% YoY to $26.3B, reflecting Medicare and Medicaid membership growth. Pharmacy & Consumer Wellness segment revenues rose 6.6% YoY to $28.9B.CVS Health reaffirmed its commitment to its strategy and long-term growth targets. The company expects to deliver low double-digit adjusted EPS growth in 2024 and beyond, driven by core business growth and strategic initiatives.
西維斯健康發佈了2023年第三季度強勁的業績,總收入同比增長10.6%,達到898億美金,調整後的每股收益爲2.21美金,超出預期。公司將2023年全年GAAP每股收益指導上調至6.37-6.61美金,調整後的每股收益指導上調至8.50-8.70美金。醫療服務部門的收入同比增長8.4%,達到469億美金,主要受藥房索賠增長和品牌通貨膨脹的驅動。醫療保健福利部門的收入同比增長16.9%,達到263億美金,反映出醫療保險和醫療補助成員的增長。藥房與消費健康部門的收入同比增長6.6%,達到289億美金。西維斯健康重申了其對策略和長期增長目標的承諾。公司預計在2024年及以後,將實現低雙位數的調整後每股收益增長,這將由核心業務增長和戰略舉措驅動。
西維斯健康發佈了2023年第三季度強勁的業績,總收入同比增長10.6%,達到898億美金,調整後的每股收益爲2.21美金,超出預期。公司將2023年全年GAAP每股收益指導上調至6.37-6.61美金,調整後的每股收益指導上調至8.50-8.70美金。醫療服務部門的收入同比增長8.4%,達到469億美金,主要受藥房索賠增長和品牌通貨膨脹的驅動。醫療保健福利部門的收入同比增長16.9%,達到263億美金,反映出醫療保險和醫療補助成員的增長。藥房與消費健康部門的收入同比增長6.6%,達到289億美金。西維斯健康重申了其對策略和長期增長目標的承諾。公司預計在2024年及以後,將實現低雙位數的調整後每股收益增長,這將由核心業務增長和戰略舉措驅動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息